SPARC Grants | Priorities and Goals | Grant Types, Timelines, and Eligibility | Mentorship and Support | Selection Advisory Group | Application  Awardees


There are four major priorities within the SPARC Grants, and applicants may choose to address one (for a Campaign Grant) or several (for a Network Grant).

  • Patient Navigation: Developing adapted health information and/or support services for advanced breast cancer patients. The purpose will be to improve the patient’s ability to navigate diagnosis, treatment, care, and/or palliation (depending on the needs in your setting). Additional elements may pertain to: informed or shared decision-making, understanding the role of clinical trials, and/or social support needed for both patients and their loved ones. 
  • Voices for Change: Amplifying the patient’s voice in health systems and health policy. The purpose will be to augment the patient’s perspective in the eyes of policy-makers, especially related to the ways in which robust monitoring for recurrence and metastatic disease can lead to cost-effective improvements in survival, quality of life, and add productive years to families and society. 
  • National Planning: Improving the national response to the diagnosis and management of advanced breast cancer. The purpose will be to provide planners and policy-makers with guidance on the unique challenges of metastatic disease, and how to address these challenges in the National Cancer Control Plan. Additional elements may pertain to: clarity of treatment guidelines, necessity of supportive care, and ensuring equitable access to care.
  • Earlier Diagnoses: Decreasing the incidence rate of de novo advanced breast cancer. The purpose will be to improve early diagnosis strategies to drive down the incidence of metastatic disease at diagnosis (i.e. de novo disease). This could be achieved in many creative ways depending on the context.


It is the primary objective of Pfizer and the UICC to empower women living with advanced breast cancer to lead productive lives with a high quality of life at the patient level, the local level, and the systems level, and to strive to reduce the incidence of de novo advanced disease. Organizations that propose new programs or to meet new goals will be considered; (funding is not available for projects already being run by an organization).  

Faced with such a massive burden of disease globally, we must better understand response methods, metrics and evaluation of success, transferability, and sustainability. Thus, the core granting priority is impact – the ways in which the proposed program or initiative will not only fill gaps in the cascade or services and wraparound services but also how gains will be measured and maintained. Thus, an applicant’s ability to demonstrate or explain how their initiative will create lasting change is a central focus of the selection criteria. Furthermore, an applicants ability to explain how that change will be maintained over time will also be evaluated. Preference may be given to those organizations that can provide examples of how they have implemented impactful programs in the past, measured outcomes, and sustained progress over time.